RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

NCT06385873 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: RC48
DRUG: Adebrelimab
DRUG: Apatinib
DRUG: S-1

Sponsor

The First Affiliated Hospital with Nanjing Medical University